Mosaic ImmunoEngineering (CPMV) Non Operating Income (2018 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Non Operating Income of -$20549.0 for Q1 2026, down 213.92% year-over-year from $18038.6 in Q1 2025, and up 2.17% quarter-over-quarter from -$21004.0 in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Non Operating Income (2018 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Non Operating Income history runs 9 years deep, the most recent figure standing at -$20549.0 for Q1 2026.
- In Q1 2026, Non Operating Income fell 213.92% year-over-year to -$20549.0; the TTM figure through Mar 2026 stood at -$83330.0 (down 211.54% YoY), while the FY2025 annual figure was -$69327.0, down 73.63% from the prior year.
- Non Operating Income for Q1 2026 stood at -$20549.0, up from -$21004.0 in the prior quarter.
- The five-year high for Non Operating Income was $372118.0 in Q2 2023, with the low at -$43506.0 in Q2 2022.
- The 5-year median for Non Operating Income is -$19940.0 (2023), against an average of $30187.1.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income tumbled 689060.0% in 2022, then soared 955.33% in 2023.
- Mosaic ImmunoEngineering's Non Operating Income stood at -$36548.0 in 2022, then jumped by 45.44% to -$19940.0 in 2023, then soared by 97.56% to -$487.0 in 2024, then plunged by 4212.94% to -$21004.0 in 2025, then increased by 2.17% to -$20549.0 in 2026.
- Business Quant data shows CPMV's Non Operating Income at -$20549.0 in Q1 2026, -$21004.0 in Q4 2025, and -$21003.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | -20,549.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,549.00 |
| Dec 31, 2025 | -21,004.00 |
| Sep 30, 2025 | -21,003.00 |
| Jun 30, 2025 | -20,774.00 |
| Mar 31, 2025 | -6,546.00 |
| Dec 31, 2024 | -487.00 |
| Sep 30, 2024 | -300.00 |
| Jun 30, 2024 | -19,415.00 |
| Mar 31, 2024 | -19,726.00 |
| Dec 31, 2023 | -19,940.00 |
| Sep 30, 2023 | -21,375.00 |
| Jun 30, 2023 | 372,118.00 |
| Mar 31, 2023 | 63,130.00 |
| Dec 31, 2022 | -36,548.00 |
| Sep 30, 2022 | 363,554.00 |
| Jun 30, 2022 | -43,506.00 |
| Mar 31, 2022 | -34,448.00 |
| Dec 31, 2021 | -25,309.00 |
| Sep 30, 2021 | -86,886.00 |
| Jun 30, 2021 | -68,722.00 |